Special Issue "New Trends in SARS-CoV-2 Variants and Vaccines"
Deadline for manuscript submissions: 20 March 2024 | Viewed by 10596
Interests: HLA; GWAS; WGS; KIR; LILRA; COVID-19; hepatitis-B; SNPs
Special Issues, Collections and Topics in MDPI journals
COVID-19 vaccines have been proven to be a game-changing tool in preventing severe cases of COVID-19. To date, four major vaccines have received approval from several countries. These vaccines are mainly based on two different forms of technology: (1) messenger ribonucleic acid (mRNA) vaccines produced by Pfizer-BioT162b2 (BNT162b2) and Moderna (mRNA-1273), and (2) vector-based replication-deficient vaccines based on chimpanzee adenoviruses (ChAdOx1 nCOV-19, AZD1222 by AstraZeneca) and human cells (Ad26.COV2 by Janssen). Interpersonal differences in terms of the short- and long-term immune responses against SARS-CoV-2 infection after vaccination have been reported. The host genetics of the vaccine recipient and COVID-19 strains are central to the evaluation of the long-term sustainability of COVID-19 vaccines. In the current Special Issue, original research articles and reviews are invited for submission. The research areas of interest may include (but are not limited to) the following topics: host genetic markers, immune response markers, vaccine efficacies and COVID-19 strains, population-based COVID-19 vaccine efficacy studies, and the side-effects of COVID-19 vaccines.
I look forward to receiving your contributions.
Dr. Seik-Soon Khor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.